Search Results

Phanes Therapeutics, Inc. today announced that it has entered into a research collaboration with Xyphos Biosciences, Inc. an Astellas Company.

Astellas Pharma Inc. and Poseida Therapeutics, Inc. today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, “Xyphos”) and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR® programs by combining the innovative cell therapy platforms from each of the companies.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Xyphos Biosciences, Inc. (CEO: James Knighton, “Xyphos”) today announced that Astellas has acquired Xyphos.

AbSci, a pioneering synthetic biology company enabling drug discovery and biomanufacturing of next-generation biotherapeutics, today announced that it has partnered with Xyphos Biosciences, an Astellas Company, to screen and identify a variant of Xyphos’ MicAbody™ lead candidate for optimal manufacturing cell line development.

Astellas Pharma Inc. and Kelonia Therapeutics announced that Xyphos Biosciences, Inc., and Kelonia have entered into a research collaboration and license agreement to develop novel Immuno-Oncology therapeutics.

Patent Protects Xyphos’ Advanced Cell-based Cancer Therapies

Phenomic AI Inc. (“Phenomic”), a biotech company developing therapies for stroma-rich tumors using its scTx® single cell transcriptomics platform, has entered into a strategic research collaboration with Astellas Pharma Inc., “Astellas” through Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas).

Gladstone researchers Warner C. Greene and Eytan Herzig collaborated with Xyphos Biosciences, Inc., to develop a novel immunotherapy for HIV.